Narcolepsy: Epidemiology Forecast to 2016-2018 with an Outlook to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 5, 2018--The “Narcolepsy- Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.
The report covers detailed overview of Narcolepsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
The report provides the insight about the historical and forecasted patient pool of Narcolepsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.
The report assesses the disease risk and burden and highlights the unmet needs of the disease.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The report provides the segmentation of the disease epidemiology by narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases in 7MM.
Key Strengths10 Year Forecast of Narcolepsy epidemiology 7MM Coverage Total Prevalent Cases of Narcolepsy Prevalent Cases according to segmentation: Narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases Diagnosed cases of Narcolepsy
Key AssessmentsPatient Segmentation Disease Risk & Burden Risk of disease by the segmentation Factors driving growth in a specific patient population
Key Topics Covered
1. Key Insights
2. Disease Background and Overview: Narcolepsy 2.1. Introduction 2.2. Signs and Symptoms 2.3. Complications 2.4. Pathophysiology 2.5. Etiology 2.6. Risk Factors 2.7. Diagnosis 2.8. Treatment
3. Epidemiology and Patient Population 3.1. Key Findings 3.2. Population and Forecast Parameters
4. 7MM Total Prevalent Patient Population of Narcolepsy 4.1. United States 4.2. Germany 4.3. France 4.4. Italy 4.5. Spain 4.6. United Kingdom 4.7. Japan
5. Market Drivers
6. Market Barriers
8. Report Methodology 8.1. Sources Used
For more information about this report visit https://www.researchandmarkets.com/research/dzqxs5/narcolepsy?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180705005296/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/05/2018 09:47 AM/DISC: 07/05/2018 09:46 AM